Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment

被引：32

作者：

Gilliam, Bruce L. ^{[1
]}

Heredia, Alonso ^{[1
]}

DeVico, Anthony ^{[1
]}

Le, Nhut ^{[1
]}

Bamba, Douty ^{[1
]}

Bryant, Joseph L. ^{[1
]}

Pauza, C. David ^{[1
]}

Redfield, Robert R. ^{[1
]}

机构：

[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA

来源：

AIDS | 2007年 / 21卷 / 15期

关键词：

D O I：

10.1097/QAD.0b013e3282f02a4f

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

G1 cytostatic drugs reduce CCR5 co-receptor expression and enhance the antiviral activity of a CCR5 antagonist in vitro. The administration of rapamycin, a G1 cytostatic agent, to three cynomolgous macaques led to decreased CCR5 messenger RNA expression in peripheral blood mononuclear cells and cervicovaginal tissue. These results support further clinical evaluation of G1 cytostatic agents such as rapamycin targeting the downregulation of CCR5 expression as a strategy for both the prevention and treatment of HIV infection.

引用

页码：2108 / 2110

页数：3

共 50 条

[21] CCR5 genotype and the clinical course of HIV-1 infection
Scribner, CL
ANNALS OF INTERNAL MEDICINE, 1998, 128 (09) : 780 - 780
[22] Investigating HIV-1 Resistance to CCR5 Antagonist Maraviroc for the Design of New Prevention Strategies
Flynn, Jacqueline K.
Roche, Michael
Paukovics, Geza
Salimi, Hamid
Duncan, Renee C.
Moore, Miranda S.
Ellet, Anne
Gray, Lachlan R.
Jubb, Becky
Westby, Mike
Purcell, Damian F. J.
Lewin, Sharon R.
Lee, Benhur
Payne, Richard J.
Churchill, Melissa J.
Gorry, Paul R.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A212 - A212
[23] CCR5 Utilization of Transmitted and Early Founder HIV-1 Envelopes and the Sensitivity to Small CCR5 Inhibitors
Hu, Q.
Keele, B.
Ping, L.
Grayson, T.
Sun, C.
Hahn, B.
Shattock, R.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 6 - 6
[24] Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 inhibitors
Henrich, T. J.
Lewine, N.
Lee, S-H
Rao, S.
Berro, R.
Greaves, W.
Gulick, R.
Tsibris, A.
Moore, J.
Kuritzkes, D.
ANTIVIRAL THERAPY, 2011, 16 : A59 - A59
[25] Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection
Kim, D
Wang, LP
Caldwell, CG
Chen, P
Finke, PE
Oates, B
MacCoss, M
Mills, SG
Malkowitz, L
Gould, SL
DeMartino, JA
Springer, MS
Hazuda, D
Miller, M
Kessler, J
Danzeisen, R
Carver, G
Carella, A
Holmes, K
Lineberger, J
Schleif, WA
Emini, EA
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (24) : 3099 - 3102
[26] How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection
van Lunzen, Jan
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 435 - 440
[27] Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection
Kuemmerle, Tim
Lehmann, Clara
Hartmann, Pia
Wyen, Christoph
Faetkenheuer, Gerd
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1773 - 1785
[28] Effect of CCR5 inhibitors on immune activation in subjects with suppressed HIV-1 RNA levels
Scourfield, A.
Waters, L.
Gazzard, B.
Kelleher, P.
Nelson, M.
Steel, A.
HIV MEDICINE, 2011, 12 : 24 - 24
[29] CCR5 cell surface density and HIV-1 envelope sequences govern antiretroviral potency of CCR5 antagonists
Miller, MD
Lineberger, JE
Dornadula, G
Danzeisen, RC
Blau, CR
Danovich, RM
Miller, MA
Finke, PE
Oates, BD
Caldwell, CG
Chen, P
Meurer, LC
Mills, SG
Springer, MS
Petropoulos, CJ
Whitcomb, J
Huang, W
Fransen, S
Simon, AJ
Hazuda, DJ
ANTIVIRAL THERAPY, 2003, 8 (03) : U66 - U67
[30] Owl monkey CCR5 reveals synergism between CD4 and CCR5 in HIV-1 entry
Nahabedian, John
Sharma, Amit
Kaczmarek, Maryska E.
Wilkerson, Greg K.
Sawyer, Sara L.
Overbaugh, Julie
VIROLOGY, 2017, 512 : 180 - 186

← 1 2 3 4 5 →